Statistics at a Glance
At a Glance
Estimated New Cases in 2023 20,380
% of All New Cancer Cases 1.0%
Estimated Deaths in 2023 11,310
% of All Cancer Deaths 1.9%
|Year||Rate of New Cases — SEER 8||Rate of New Cases — SEER 12||Death Rate — U.S.||5-Year Relative Survival — SEER 8|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
New cases come from SEER 12. Deaths come from U.S. Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Rate of New Cases and Deaths per 100,000: The rate of new cases of acute myeloid leukemia was 4.1 per 100,000 men and women per year. The death rate was 2.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2016–2020 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 0.5 percent of men and women will be diagnosed with acute myeloid leukemia at some point during their lifetime, based on 2017–2019 data.
Prevalence of This Cancer: In 2020, there were an estimated 73,168 people living with acute myeloid leukemia in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Acute Myeloid Leukemia?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 22 (Excluding IL/MA) 2013–2019. Gray figures represent those who have died from acute myeloid leukemia. Green figures represent those who have survived 5 years or more.
New Cases and Deaths
How Common Is This Cancer?
|Rank||Common Types of Cancer||Estimated New
|1.||Breast Cancer (Female)||297,790||43,170|
|3.||Lung and Bronchus Cancer||238,340||127,070|
|5.||Melanoma of the Skin||97,610||7,990|
|7.||Kidney and Renal Pelvis Cancer||81,800||14,890|
|Acute Myeloid Leukemia||20,380||11,310|
Acute myeloid leukemia represents 1.0% of all new cancer cases in the U.S.
In 2023, it is estimated that there will be 20,380 new cases of acute myeloid leukemia and an estimated 11,310 people will die of this disease.
Who Gets This Cancer?
Acute myeloid leukemia is more common in older adults and among men compared to women. AML is a relatively rare disease. The rate of new cases of acute myeloid leukemia was 4.1 per 100,000 men and women per year based on 2016–2020 cases, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||4.5|
|Non-Hispanic Asian/Pacific Islander||4.2|
|Non-Hispanic American Indian/Alaska Native||3.1|
|Non-Hispanic Asian/Pacific Islander||2.9|
SEER 22 2016–2020, Age-Adjusted
|Age Range||Percent of New Cases|
Acute myeloid leukemia is most frequently diagnosed among people aged 65–74.
SEER 22 2016–2020, All Races, Both Sexes
Who Dies From This Cancer?
Death rates from acute myeloid leukemia are higher among older adults, or those 65 and older. People with leukemia have many treatment options, and treatment for leukemia can often control the disease and its symptoms. The death rate was 2.7 per 100,000 men and women per year based on 2016–2020 deaths, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||2.3|
|Non-Hispanic Asian/Pacific Islander||2.6|
|Non-Hispanic American Indian/Alaska Native||1.4|
|Non-Hispanic Asian/Pacific Islander||1.5|
U.S. 2016–2020, Age-Adjusted
|Age Range||Percent of Deaths|
The percent of acute myeloid leukemia deaths is highest among people aged 75–84.
U.S. 2016–2020, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new acute myeloid leukemia cases have been stable over 2010–2019. Age-adjusted death rates have been falling on average 0.6% each year over 2011–2020. 5-year relative survival trends are shown below.
Interactive Statistics with SEER*Explorer
- Create custom graphs and tables
- Download data and images
- Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.Explore Additional Acute Myeloid Leukemia Statistics
More About This Cancer
Cancer and the Blood
Figure: Stem cells maturing into one of three types of mature blood cells: red blood cells, platelets, and white blood cells. Precursor cells are also shown: stem cells, myeloid blasts, lymphoid stem cells, and lymphoid blasts.
Leukemia is cancer that starts in the tissue that forms blood. Most blood cells develop from cells in the bone marrow called stem cells. In a person with leukemia, the bone marrow makes abnormal white blood cells. The abnormal cells are leukemia cells. Unlike normal blood cells, leukemia cells don't die when they should. They may crowd out normal white blood cells, red blood cells, and platelets. This makes it hard for normal blood cells to do their work. The four main types of leukemia are:
- Acute lymphoblastic leukemia (ALL)
- Acute myelogenous leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Chronic myelogenous leukemia (CML)
There is no standard staging system for leukemia. The disease is described as untreated, in remission, or recurrent.
Here are some resources for learning more about leukemia.
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/amyl.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2023 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.